Abstract:Previous studies revealed that phenylhistamines and histaprodifens possess higher potency and affinity at guinea pig histamine H(1)-receptor (gpH(1)R) than at human histamine H(1)-receptor (hH(1)R). However, we recently identified an imidazolylpropylguanidine [N(1)-(3-cyclohexylbutanoyl)-N(2)-[3-(1H-imidazol-4-yl)-propyl]guanidine (UR-AK57)] with higher potency and efficacy at hH(1)R compared with gpH(1)R. The aim of this study was to reveal the molecular basis for the species differences of synthetic ligands. We studied 11 novel phenylhistamines and phenoprodifens. H(1)R species isoforms were expressed in Sf9 insect cells, and [(3)H]mepyramine competition binding and GTPase assays were performed. We identified bulky phenylhistamines with higher potency and affinity at hH(1)R compared with gpH(1)R. Molecular dynamics simulations of ligand-H(1)R interactions revealed four potential binding modes for phenylhistamines possessing an additional histamine moiety; the terminal histamine moiety showed a high flexibility in the binding pocket. There are striking similarities in ligand properties in bulky phenylhistamines and UR-AK57. Comparison of bulky phenylhistamine binding mode with binding mode of UR-AK57 suggests that only one of these four binding modes should be established. The higher potency is explained by more effective van der Waals interaction of the compounds with Asn(2.61) (hH(1)R) relative to Ser(2.61) (gpH(1)R). In addition, two stable binding modes for phenoprodifens with different orientations in the binding-pocket were identified. Depending on phenoprodifen orientation, the highly conserved Trp(6.48), part of the toggle switch involved in receptor activation, was found in an inactive or active conformation, respectively. We identified the first phenylhistamines with higher potency at hH(1)R than at gpH(1)R and obtained insight into the binding mode of bulky phenylhistamines and imidazolylpropylguanidines.

Identification and Characterization of ZEL-H16 As a Novel Agonist of the Histamine H3 Receptor.

Identification of a HEK-293 Cell Line Containing Stably-Transfected H3 R Gene and Screening for Novel Non-Imidazole Histamine H3 Receptor Antagonists

Discovery of 18F Labeled AZD5213 Derivatives as Novel Positron Emission Tomography (PET) Radioligands Targeting Histamine Subtype‐3 Receptor

Structural Basis for Recognition of Antihistamine Drug by Human Histamine Receptor

Agonist-Induced Activation of Histamine H3 Receptor Signals to Extracellular Signal-Regulated Kinases 1 and 2 through PKC-, PLD- and EGFR-dependent Mechanisms.

Discovery of the novel and potent histamine H1 receptor antagonists for treatment of allergic diseases

Label-free cell phenotypic profiling of histamine H4R receptor and discovery of non-competitive H4R antagonist from natural products

Design, Synthesis and Biological Activity of a Novel Ethylenediamine Derivatives As H1 Receptor Antagonists.

Structural basis of ligand recognition and design of antihistamines targeting histamine H4 receptor

Novel Heterocyclic-Substituted Benzofuran Histamine H-3 Receptor Antagonists: in Vitro Properties, Drug-Likeness, and Behavioral Activity

Identification of higenamine as a novel α1 -adrenergic receptor antagonist.

Non-Imidazole Histamine H3 Ligands. Part VII. Synthesis, In Vitro and In Vivo Characterization of 5-Substituted-2-thiazol-4-n-propylpiperazines

Pharmacological characterization of seven human histamine H3 receptor isoforms

Molecular basis for the selective interaction of synthetic agonists with the human histamine H1-receptor compared with the guinea pig H1-receptor

Cross-Desensitization and Cointernalization of H1 and H2 Histamine Receptors Reveal New Insights into Histamine Signal Integration

Computational investigation of interactions between human H2 receptor and its agonists.

Studies of H4R Antagonists Using 3D-QSAR, Molecular Docking and Molecular Dynamics

Design, Synthesis, and Biological Evaluation of Novel Iso-Flavones Derivatives As H3R Antagonists

Docking and MD Study of Histamine H4R Based on the Crystal Structure of H1R

Structure-Activity Relationship of Hetarylpropylguanidines Aiming at the Development of Selective Histamine Receptor Ligands†

Progress of Histamine H3 Receptor Antagonist